HB2198 / Hinge Bio - LARVOL DELTA

Hinge Bio Raises $30 Million Series A’ Financing to Develop Next-Generation Therapies via its Proprietary GEM-DIMER Platform (GlobeNewswire) - "Hinge Bio, Inc...today announced the close of a Series A’ financing led by Point72...The proceeds will support entry of the Company’s lead product candidate, HB2198, into a Phase 1 clinical trial in patients living with Systemic Lupus Erythematosus ('Lupus') as well as development of additional therapeutics from Hinge Bio’s proprietary GEM-DIMER platform to treat diseases with high unmet need...Hinge Bio’s lead candidate from its GEM-DIMER platform, HB2198, is expected to enter clinical development during 2025."

Financing • New P1 trial • Systemic Lupus Erythematosus